Developmental Patterns of Hepatic Peroxisome Proliferator‐Activated Receptor (PPAR) Expression in Xenopus laevis and Response to Pharmaceutical Agonists During Metamorphic Climax
Open Access
- 3 September 2025
- journal article
- Published by Wiley in Journal of Experimental Zoology Part A: Ecological and Integrative Physiology
- Vol. 343 (10) , 1191-1204
Abstract
Peroxisome proliferator‐activated receptors (PPAR) are master transcriptional regulators that maintain metabolic homeostasis in vertebrates. Amphibians are often exposed to endocrine disrupting compounds (EDCs) that could dysregulate lipid metabolism. Larvae of the African clawed frog ( Xenopus laevis ) are routinely used as a model to study aquatic EDC exposures, but PPAR expression has not been characterized across larval development or metamorphosis in this species. We conducted two experiments to elucidate (a) the expression in late metamorphosis for xPPAR α / β / γ subtypes, and (b) the effect of pharmaceutical PPAR agonists (pirinixic acid, bezafibrate, and ciprofibrate) on the expression of xPPAR α / β / γ target genes. Additionally, we considered apical endpoints (body mass, body condition [scaled mass index, SMI], and relative liver mass). We hypothesized pharmaceuticals would agonize hepatic xPPAR α / β / γ , upregulating expression of downstream target genes and reducing apical endpoints with variation reflective of developmental patterns of nuclear receptor expression. We observed upregulation of xPPAR α during late premetamorphosis (NF 51), prometamorphosis (NF 56–57), and metamorphic climax (NF 58–66), which also held for xPPAR γ with exception for peak of metamorphic climax (NF 62). For xPPAR β , we only observed upregulation at conclusion of metamorphic climax (NF 66). Agonists did not cause changes in gene expression for xPPAR α / β / γ targets, but pirinixic acid exposure decreased female body condition. The dynamic hepatic expression of xPPAR α / β / γ during late metamorphosis is presumably necessary to coordinate energy flux and highlights a potential period of susceptibility to PPAR agonism. However, pharmaceuticals identified to interact with xPPARα/β/γ did not elicit a response concordant with PPAR agonism at high doses. These results suggest that X. laevis may not be a sensitive model for studies testing PPAR‐mediated effects of xenobiotics.Keywords
This publication has 48 references indexed in Scilit:
- Hepatic enzyme induction and its potential effect on thyroid hormone metabolism in the metamorphosing tadpole of Xenopus laevis (African clawed frog)Journal of Applied Toxicology, 2024
- Fatter or stronger: Resource allocation strategy and the underlying metabolic mechanisms in amphibian tadpolesComparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2021
- PPARs in liver physiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- Effects of dietary crude oil exposure on molecular and physiological parameters related to lipid homeostasis in polar cod ( Boreogadus saida )Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 2018
- 1 H NMR-based metabolomics reveals sub-lethal toxicity of a mixture of diabetic and lipid-regulating pharmaceuticals on amphibian larvaeAquatic Toxicology, 2017
- Effects of the PPARα agonist WY-14,643 on plasma lipids, enzymatic activities and mRNA expression of lipid metabolism genes in a marine flatfish, Scophthalmus maximusAquatic Toxicology, 2015
- The fat body of bullfrog (Lithobates catesbeianus) tadpoles during metamorphosis: Changes in mass, histology, and melatonin content and effect of food deprivationComparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, 2011
- Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio)Aquatic Toxicology, 2011
- Amphibian lipid levels at metamorphosis correlate to post-metamorphic terrestrial survivalOecologia, 2007
- Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptorsCell, 1992